Performance of Dupixent, which just picked up a new indication, was a third quarter highlight and bodes well for future growth, but sales of the blockbuster insulin glargine Lantus are crumbling.
Sanofi touted the promise of new launches and a return to growth in the third quarter, which helped offset the continued decline of its top-selling, but now genericized, Lantus (insulin glargine).
The company reported third quarter sales of €9.4bn ($8.3bn) on Oct. 31, which was up 6.3% year-over-year and beat the...
Glenmark signals thrust on high margin products, while exiting tail end brands as part of efforts to emerge as a branded company. In-licensed assets like Brukinsa and Tevimbra are seen as pivotal to driving growth alongside.
Pfizer showed how to come out on top with investors during earnings season. Post strong sales growth – and avoid mentioning tariffs, most favored nation pricing or Medicare modernization impacts.
The Danish firm's atopic dermatitis drug Adbry is performing well despite strong competition from Sanofi/Regeneron’s Dupixent.
Ibrance is losing share to other drugs, but Zydus looks forward to a late 2027/early 2028 launch of its generic in the US where partner Synthon might have 180-day exclusivity. In India, as Lilly launches Mounjaro KwikPen, it hopes for a GLP-1 edge with a differentiated device and formulation.
All eyes on chronic urticaria after eosinophilic esophagitis disappointment.
Glenmark signals thrust on high margin products, while exiting tail end brands as part of efforts to emerge as a branded company. In-licensed assets like Brukinsa and Tevimbra are seen as pivotal to driving growth alongside.
The total value of deals for GLP-1-associated assets so far this year is already double that of the previous two years combined, with China-originated molecules accounting for a substantial majority. Scrip takes a look at some of the key factors behind this activity.
